Coronavirus Replication and Protease Inhibitor
| Program | Discovery | Preclinical | Phase 1 | Phase 2a | Phase 2b | Phase 3 | |
|---|---|---|---|---|---|---|---|
| COVID-19 | CDI-988 Oral Protease Inhibitor |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2a Phase complete
|
Phase 2b Phase complete
|
Phase 3 Phase complete
|
| COVID-19 (Licensed) | CDI-45205 Protease Inhibitor |
Discovery Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2a Phase not started
|
Phase 2b Phase not started
|
Phase 3 Phase not started
|
| COVID-19 | Replication Inhibitors |
Discovery Phase in progress
|
Preclinical Phase not started
|
Phase 1 Phase not started
|
Phase 2a Phase not started
|
Phase 2b Phase not started
|
Phase 3 Phase not started
|
On February 24, 2020 we announced our entry into a license agreement with Kansas State University Research Foundation (KSURF) to further develop certain proprietary broad-spectrum antiviral compounds for the treatment of Norovirus and Coronavirus infections. On April 22, 2020 we announced the expansion of our previously announced license agreement with KSURF to include rights to additional preclinical leads and further develop certain proprietary broad-spectrum antiviral compounds for the treatment of COVID-19.
Under the terms of the agreement, Cocrystal has been granted an exclusive, royalty-bearing right and license to certain small molecule therapeutic inhibitors against coronaviruses, picornaviruses and caliciviruses covered by patent rights controlled by KSURF. We intend to pursue research and development of these antiviral compounds for coronavirus, including preclinical and clinical development. This license significantly expands and further advances our COVID-19 program by providing more targeted, potent compounds for further development.
The additional compounds licensed from KSURF have demonstrated both in vitro and in vivo activity in animal models against the viral pathogens MERS and SARS, which are coronaviruses that are structurally similar to SARS-CoV-2.
We initiated preclinical studies of COVID-19 inhibitors during the second quarter of 2020 and plan to identify additional COVID-19 inhibitors utilizing our proprietary platform technology. We announced the selection of a lead preclinical molecule in the fourth quarter of 2020.